Medtronic Plc

Most Recent

  • uploads///REVENUE GUIDANCE
    Company & Industry Overviews

    The Impact of Dispensing Business Changes on BD’s Revenue

    US dispensing business headwinds BD (BDX) has introduced some changes to its US dispensing business as part of its efforts to transform its medication management solutions. The initiative has impacted the company’s performance due to related accounting changes. For details, read Headwind for Becton Dickinson: US Dispensing Business. These changes had a higher-than-expected impact in 3Q17 and 4Q17, and […]

    By Sarah Collins
  • uploads///capital allocation
    Company & Industry Overviews

    Johnson & Johnson’s Latest Dividend Payment: Is It Important?

    Johnson & Johnson (JNJ) announced a quarterly cash dividend of $0.80 per share on July 18, 2016, payable on September 6, 2016. This is the same as the previous quarter.

    By Sarah Collins
  • uploads///SAFETY REVENUES
    Company & Industry Overviews

    How BD Is Accelerating Its Safety Revenues after Flat Growth in 3Q17

    Becton Dickinson (BDX), or BD, acquired the global safety products portfolio through the acquisition of CareFusion in 2015.

    By Sarah Collins
  • uploads///SPLS
    Fund Managers

    CalPERS raises position in Staples

    Staples began discussions to acquire Office Depot in September 2014. Staples will acquire all outstanding Office Depot shares in the $6.3 billion deal.

    By Samantha Nielson
  • uploads///eps
    Earnings Report

    What to Expect from St. Jude Medical’s Earnings in 2Q16

    In 1Q16, St. Jude Medical exceeded analysts’ EPS (earnings per share) estimate of $0.89 as well as the revenue estimate of ~$1.4 billion.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    How Long Will Stryker Stock Sustain Its Bullish Trend?

    Stryker (SYK) closed at $145.4 on July 18, 2017. It has a 50-day moving average of $141.8 and a 200-day moving average of $132.6.

    By Sarah Collins
  • Healthcare

    Farallon Capital adds a new position in Covidien

    Ireland-based Covidien is a global healthcare leader that offers innovative medical technology solutions and patient care products to providers.

    By Patricia Garner
  • uploads///analyst recommendations
    Company & Industry Overviews

    Most Analysts Rate Boston Scientific a ‘Buy’

    Based on the recommendations of 27 brokerage firms in a Bloomberg survey, about 78% gave Boston Scientific a consensus rating of “buy.”

    By Sarah Collins
  • uploads///analyst recommendations
    Company & Industry Overviews

    How Wall Street Reacted to the Delay in BSX’s Lotus Edge Launch

    Boston Scientific (BSX) announced the delay in the commercialization timelines of BSX’s Lotus devices in Europe and the US on November 28, 2017.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    What Does Johnson & Johnson Predict for Its Medical Devices Segment?

    Johnson & Johnson’s (JNJ) medical devices segment deals with vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care.

    By Mike Benson
  • uploads///revenue estimates
    Earnings Report

    What Analysts Predict for Thermo Fisher’s 2Q17 Revenues

    Wall Street estimates that Thermo Fisher Scientific’s (TMO) 2Q17 revenue will come in at ~$4.9 billion, a rise of ~8.5% on a YoY (year-over-year) basis.

    By Sarah Collins
  • uploads///analyst recommendations
    Earnings Report

    Analysts Recommend Boston Scientific as a Strong ‘Buy’

    Boston Scientific will release its 1Q16 earnings results on April 27. In a survey of 28 brokerage firms, about 78.6% of the firms rated Boston Scientific as a “buy.”

    By Sarah Collins
  • uploads///chair _
    Earnings Report

    Dentsply Sirona’s Segments: Q2 2018 Performance

    Since its second-quarter earnings release on July 7, Dentsply Sirona (XRAY) stock has plummeted ~20%.

    By Kenneth Smith
  • uploads///revenue estimates
    Earnings Report

    Will Medtronic Maintain Its Revenue Growth Momentum in Fiscal 1Q18?

    In fiscal 1Q18, Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.45 billion, which represents a rise of ~4% in comparison to its fiscal 1Q17 revenue of $7.17 billion.

    By Sarah Collins
  • uploads///eps estimates
    Earnings Report

    Could Johnson & Johnson’s Earnings Grow in 3Q16?

    Analysts’ estimates Johnson & Johnson (JNJ) accounts for ~6.3% of the total holdings of the iShares Core High Dividend ETF (HDV). The company has managed to exceed analysts’ earnings estimates for the last several quarters. The movement in a company’s share price is generally impacted by the deviation of its actual results from analysts’ estimates. Usually, a stock’s […]

    By Sarah Collins
  • uploads///Chart  Revenues
    Earnings Report

    Johnson & Johnson’s 4Q15 Estimates: Revenues Will Fall

    On an annual basis, Johnson & Johnson’s revenues have increased over the past few years following the restructuring of its business segments and strong performance of some of its key products.

    By Mike Benson
  • uploads///af
    Company & Industry Overviews

    Trial Progression of St. Jude Medical’s Stroke Prevention Device

    On September 1, St. Jude Medical (STJ) launched its AMPLATZER Amulet IDE trial that will expand the device’s access to atrial fibrillation patients.

    By Sarah Collins
  • uploads///REVENUE ESTIMATES
    Earnings Report

    Analysts Expect Medtronic’s Revenue to Rise 4% in Fiscal 4Q17

    Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.9 billion in fiscal 4Q17, a rise of ~4% compared to its fiscal 4Q16 revenue of $7.6 billion.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Analyst Recommendations for Stryker: Most Say ‘Buy’

    In a Reuters survey of 27 brokerage companies, about 63.0% of analysts have rated Stryker a “buy,” and 26.0% have rated it a “hold.”

    By Sarah Collins
  • uploads///analyst recommendations
    Company & Industry Overviews

    What Analysts Are Saying about Becton Dickinson Now

    Analysts estimate that Becton Dickinson has a potential to return ~6.4% over the next 12 months. The 12-month target price for BDX is $163.10 per share.

    By Sarah Collins
  • uploads///projections
    Earnings Report

    What to Expect from Edwards Lifesciences’ Fiscal 3Q17 Results

    Edwards Lifesciences (EW) has scheduled its 3Q17 earnings release for October 24, 2017. This leading player in the artificial heart valves market has been gaining momentum and trading near its 52-week high.

    By Sarah Collins
  • uploads///recommendations
    Earnings Report

    Stryker: Analysts’ Recommendations before Its 3Q17 Earnings

    Stryker (SYK), the second-largest orthopedic device developer, is set to announce its 3Q17 earnings results on October 26, 2017.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    A Look at Abbott Laboratories’ Valuation Multiples

    May 3, Abbott Laboratories had a 12-month forward PEG ratio of ~1.5x, compared to the ~1.6x PEG multiple recorded in April.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    How Has Medtronic’s Stock Performed Recently?

    Medtronic (MDT) was trading at $80.3 on November 15, 2016. It had a 50-day moving average of $83.7 and a 200-day moving average of $84.8.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    A Look at Boston Scientific’s Valuation Multiples in September

    On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.

    By Sarah Collins
  • uploads///tablets _
    Earnings Report

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson surpassed Wall Street analysts’ estimates for EPS (or earnings-per-share) and revenues in 1Q18.

    By Mike Benson
  • uploads///diabetes _
    Company & Industry Overviews

    Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump

    Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.

    By Sarah Collins
  • uploads///revenue estimates
    Earnings Report

    Medtronic’s Revenue Is Estimated to Rise in Fiscal 2Q17

    On November 22, 2016, Medtronic (MDT) will announce its fiscal 2Q17 earnings for the period that ended on October 31, 2016.

    By Sarah Collins
  • uploads///diabetes
    Company & Industry Overviews

    FDA Approves Medtronic’s Enlite Sensor for iPro2 CGM System

    Medtronic (MDT) is consistently working on expanding access to and improving diabetes management via new and enhanced products and services.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results

    On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.

    By Sarah Collins
  • uploads///animas exit from insulin pump business
    Company & Industry Overviews

    Tandem Diabetes Care’s International Expansion Strategy

    Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.

    By Sarah Collins
  • uploads/// sales guidance
    Company & Industry Overviews

    Edwards Lifesciences and Boston Scientific: Patent Dispute Update

    Edwards Lifesciences’ and Boston Scientific’s patent dispute On March 23, 2018, Edwards Lifesciences (EW) announced that it won its dispute with Boston Scientific (BSX) over US Patent 8992608. The USPTO (US Patent and Trademark Office) decided in favor of Edwards in an inter partes review filed by Boston Scientific against Edwards for its TAVR (transcatheter aortic valve replacement) technology, finding […]

    By Sarah Collins
  • uploads///consumer business
    Consumer

    JNJ’s Consumer Business Expected to Be Driven by Innovation

    Johnson & Johnson started shipments of its revamped baby care line in July, which is expected to register improved performance in the third quarter.

    By Sarah Collins
  • uploads///piron guillaume  unsplash
    Earnings Report

    Analysts Raise Target Prices on ABT ahead of Q3 Earnings

    Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.

    By Sarah Collins
  • uploads///COV MDT overlap
    Healthcare

    Antitrust approvals: Assessing the Covidien-Medtronic merger

    The Covidien (COV)–Medtronic (MDT) deal is based on complementary products, not necessarily buying out a competitor.

    By Brent Nyitray, CFA, MBA
  • uploads///Technologies
    Miscellaneous

    How Much Can Truven’s Data Actually Benefit IBM’s Watson?

    IBM intends to strengthen its presence in cognitive computing and machine learning space through Watson, which requires a vast pool of data.

    By Anne Shields
  • uploads///DIABETES
    Earnings Report

    What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?

    Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.

    By Sarah Collins
  • uploads///segment revenues
    Company & Industry Overviews

    How Will the Lotus Recall Affect BSX’s 2017 Performance?

    Boston Scientific has begun implementing the necessary fixes for its Lotus Valve system, and it expects to relaunch the product in the Europe and other international markets in 4Q17.

    By Sarah Collins
  • uploads///CVG
    Company & Industry Overviews

    How Medtronic’s Cardiac and Vascular Group Performed

    Medtronic’s (MDT) Cardiac & Vascular Group generated revenues of $2.9 billion in the second quarter of fiscal 2019 compared to $2.8 billion in the second quarter of fiscal 2018.

    By Daniel Collins
  • uploads///CASH FLOW
    Company & Industry Overviews

    How Tax Reform Affected Medtronic’s 3Q18 Performance

    Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]

    By Sarah Collins
  • uploads///RECONSTRUCTUVE MARKET POSITION
    Company & Industry Overviews

    What Zimmer Biomet’s Progress II Study Success Could Mean

    On December 22, 2017, Zimmer Biomet Holdings (ZBH) published the results of its Progress II trial, and the results were positive.

    By Sarah Collins
  • uploads///minimed g launch dynamics
    Company & Industry Overviews

    Diabetes Management Breakthrough: Medtronic’s MiniMed 670G

    On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.

    By Sarah Collins
  • uploads///diabetes _
    Company & Industry Overviews

    Why Senseonics Holdings Is Up ~5.6% Today

    Today, Senseonics Holdings (SENS) is trading higher than yesterday’s close of $4.43 per share. The stock was up ~5% in premarket trading and is trending higher since then.

    By Sarah Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings

    Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.

    By Peter Neil
  • uploads///insulin syringe _
    Company & Industry Overviews

    Analysts’ Views on Tandem Diabetes Care after Its FDA Approval

    After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump.

    By Sarah Collins
  • uploads///
    Miscellaneous

    Fitbit’s Team Strategy: The Benefits of Acquisitions and Partnerships

    In 2016, Fitbit (FIT) inked a deal with Pebble to harvest certain Pebble assets, now that the latter company has begun shutting down operations.

    By Adam Rogers
  • uploads///CVG SEGMENT PERFORMANCE
    Company & Industry Overviews

    Here’s What Could Boost Medtronic’s Growth in Fiscal 2019

    Medtronic’s CSH division’s growth was driven by the constant currency growth of its transcatheter aortic valves.

    By Sarah Collins
  • uploads///aid __
    Company & Industry Overviews

    Boston Scientific Expands Its Endoscopy Business with EMcision Acquisition

    On March 5, 2018, Boston Scientific (BSX) announced the acquisition of EMcision, which will expand the company’s endoscopy business.

    By Sarah Collins
  • uploads///minimed g
    Company & Industry Overviews

    Medtronic’s Key Growth Driver: MiniMed 670G Hybrid Closed Loop

    Medtronic’s Diabetes Group performance in fiscal Q4 2018 was driven by a 25% growth for its MiniMed 670G hybrid closed-loop insulin pump.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    ABT’s Recent Stock Slump: What’s behind the Decline?

    On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share.

    By Sarah Collins
  • uploads///CASH AND INVESTMENTS
    Earnings Report

    What’s Intuitive Surgical’s Capital Allocation Strategy?

    On December 13, 2016, Intuitive Surgical increased its authorized share repurchase program from $1.0 billion to $3.0 billion.

    By Sarah Collins
  • uploads///strategy
    Company & Industry Overviews

    Johnson & Johnson Accepts Sale of Its LifeScan Business

    On June 12, Johnson & Johnson (JNJ) announced it had accepted a $2.1 billion offer for the sale of its LifeScan business, which manufactures blood glucose monitoring devices and OneTouch products, from private equity company Platinum Equity.

    By Sarah Collins
  • uploads///thv
    Earnings Report

    What Led to Edwards Lifesciences’ Stellar Performance in 1Q16?

    Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$366 million was contributed by the company’s THV (Transcatheter Heart Valve) Therapy segment.

    By Sarah Collins
  • uploads///share price on Oct
    Earnings Report

    ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade

    On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.

    By Sarah Collins
  • uploads///hush naidoo  unsplash
    Earnings Report

    Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results

    Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.

    By Sarah Collins
  • uploads///blood pressure monitor _
    Company & Industry Overviews

    Medtronic: Wall Street’s Views and Latest Recommendations

    On May 31, Medtronic had a consensus 12-month target price of $93.81, implying a 12-month investment return potential of ~9.2%.

    By Sarah Collins
  • uploads///DIABETES BUSINESS PERFORMANCE
    Earnings Report

    How the Freestyle Libre CGM Opportunity Is Playing Out for ABT

    Abbott Laboratories stated during its second-quarter earnings release that it’s on track for achieving its fiscal 2018 guidance for Libre.

    By Sarah Collins
  • uploads///diabetes _
    Earnings Report

    Analysts’ Recent Recommendations and Target Price for ABT Stock

    On May 2, a Reuters survey noted that of 20 brokerage firms tracking Abbott Laboratories, 16 analysts recommended a “buy” or a “strong buy.”

    By Sarah Collins
  • uploads///progress _
    Company & Industry Overviews

    Discussing Boston Scientific’s Stock Performance in 2018 So Far

    On July 9, Boston Scientific (BSX) stock ended the trading day at $33.79, a rise of ~0.50% compared to the previous day.

    By Sarah Collins
  • uploads///lotus edge
    Company & Industry Overviews

    Boston Scientific’s Lotus Edge Valve System Gets Approval in Europe

    Boston Scientific (BSX) is consistently working towards gaining higher market share in the attractive TAVR (transcatheter aortic valve replacement) market in Europe.

    By Sarah Collins
  • uploads///eps estimates
    Earnings Report

    Will Medtronic Meet Analysts’ Earnings Estimates in Fiscal 1Q18?

    For the last several quarters, Medtronic has consistently exceeded analysts’ earnings estimates.

    By Sarah Collins
  • uploads///REVEUE ESTIMATES
    Earnings Report

    Can Intuitive Surgical’s Revenue Grow in 2017?

    On July 20, 2017, Intuitive Surgical (ISRG) will announce its 2Q17 earnings. The company has exceeded analysts’ revenue estimates for the last several quarters.

    By Sarah Collins
  • uploads///anatomy _
    Company & Industry Overviews

    What Triggered a 52-Week High for Boston Scientific in October?

    On October 2, Morgan Stanley raised its target price for BSX stock. That day, BSX stock was trading at its 52-week high.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Tandem Diabetes Care’s Stock Performance This Month

    On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.

    By Sarah Collins
  • uploads///freestyle libre
    Company & Industry Overviews

    Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects

    According to Abbott Laboratories, around two-thirds of diabetes patients have Type-1 diabetes while the rest have Type-2 diabetes.

    By Sarah Collins
  • uploads///price history
    Company & Industry Overviews

    Will Intuitive Surgical Stock Witness Continued Growth Momentum?

    Intuitive Surgical (ISRG) has returned approximately 48.2% YTD (year-to-date), surpassing SPY as well as the Health Care Select Sector SPDR Fund (XLV) by enormous margins.

    By Sarah Collins
  • uploads///stock performance
    Earnings Report

    Abbott Laboratories’ Stock Price Performance in July

    Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.

    By Sarah Collins
  • uploads///Chart  Rev
    Earnings Report

    Sanofi’s 1Q18: Revenue Expected to Fall

    Sanofi’s 1Q18 revenue estimates As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations. Structure of the group The above graph shows Sanofi’s revenue since 1Q17 and estimates for 1Q18. In 2016, Sanofi reorganized its businesses into five units: Sanofi Genzyme, its specialty care business, which […]

    By Mike Benson
  • uploads///hush naidoo  unsplash
    Company & Industry Overviews

    Trade War Fears Triggered Medtronic’s Stock Decline on March 23

    Following heightened concerns of a US–China trade war, Medtronic (MDT) stock hit its 52-week low of $76.41 on March 23, 2018.

    By Sarah Collins
  • uploads///highlights
    Company & Industry Overviews

    Can BAX Stock Maintain Momentum after Recent Highs?

    BAX stock plummeted in late 2016 but has witnessed a rise in recent months, trading at a 52-week high on October 27, 2017.

    By Sarah Collins
  • uploads///mitg segment performance
    Company & Industry Overviews

    Innovative Products Driving Medtronic’s Growth

    Medtronic expects its MITG segment to have an organic growth rate of 4% in fiscal 2019.

    By Sarah Collins
  • uploads///VALUATION
    Company & Industry Overviews

    How Edwards Lifesciences Trades Compared to Its Peers

    As of August 30, 2016, Edwards Lifesciences (EW) was trading at a forward PE (price-to-earnings) multiple of 40x.

    By Sarah Collins
  • uploads///neuromodulation
    Company & Industry Overviews

    St. Jude’s Proclaim Elite SCS System Received CE Mark Approval

    On December 8, 2016, St. Jude Medical (STJ) announced CE Mark approval for full body MR (magnetic resonance) conditional labeling for the Proclaim Elite SCS (spinal cord stimulation) System.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    How Has Boston Scientific Stock Performed Recently?

    Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.

    By Sarah Collins
  • uploads///AdobeStock_
    Macroeconomic Analysis

    An Investor’s Guide to Top-Performing Stocks for 2020

    Overall, tech stocks turned out to be the top performers for 2019. The gain in the technology sector helped the S&P 500 gain 29% in 2019.

    By Rabindra Samanta
  • uploads///RTG
    Company & Industry Overviews

    Medtronic’s Spine Business Dynamics amid a Challenging Market

    In fiscal 2Q18, Medtronic’s Restorative Therapies Group business registered year-over-year sales growth of ~2.0%, which came in below expectations due to the negative impact of Hurricane Maria.

    By Sarah Collins
  • uploads///innovation strategies
    Company & Industry Overviews

    How Johnson & Johnson’s Partnerships Enhance Customer Value

    Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.

    By Sarah Collins
  • uploads///GUARDIAN CONNECT
    Company & Industry Overviews

    Guardian Connect Expected to Be Medtronic’s Big Opportunity

    On March 12, Medtronic announced that it has received FDA approval for its stand-alone continuous glucose monitoring system Guardian Connect.

    By Sarah Collins
  • uploads///hospital _
    Earnings Report

    Analysts’ Views on Abbott Laboratories before Q2 2018 Earnings

    On July 18, Abbott Laboratories (ABT) is expected to release its earnings results for its fiscal second quarter of 2018.

    By Sarah Collins
  • uploads///q highlights
    Company & Industry Overviews

    BD Stock Reaches 52-Week High on November 27

    BD released its 4Q17 and fiscal 2017 earnings results on November 2, 2017. That day, the stock rose ~7.7%, registering a record high thanks to the company’s stellar earnings results.

    By Sarah Collins
  • uploads///hand __
    Company & Industry Overviews

    BSX Stock Regains Momentum after Its Recent Bearish Trend

    On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    ZBH Stock Price Momentum Likely to Trend Upward

    On January 24, Zimmer Biomet Holdings (ZBH) closed trading at a share price of $125.02. The company traded at a 52-week high of $133.49 on July 17, 2017.

    By Sarah Collins
  • uploads///revenue estimates
    Company & Industry Overviews

    Stryker’s Recent Stock Price Movement: Upside Potential?

    Stryker stock has registered slightly volatile activity in the past few months. However, the stock largely remains on a bullish trajectory.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    A Look at Medtronic’s Recent Stock Performance

    Medtronic (MDT) was trading at $83.9 on May 22, 2017. It had a 50-day moving average of $82.1 and a 200-day moving average of $78.4.

    By Sarah Collins
  • uploads///ecg _
    Company & Industry Overviews

    Abbott Laboratories Continues Its Bull Run with a Record High

    On September 26, Abbott Laboratories (ABT) ended the trading day at $72.84, up ~0.89% from the previous day’s close.

    By Sarah Collins
  • uploads///cvg segment
    Company & Industry Overviews

    Strong TAVR Adoption Is a Key Growth Driver for MDT’s CVG Business

    Medtronic’s CVG (Cardiac and Vascular Group) business reported growth of ~7.0% on a YoY (year-over-year) basis.

    By Sarah Collins
  • Healthcare

    Must-know: Key export barriers for medical device manufacturers

    Most large U.S. manufacturers have invested significant capital into emerging markets, including Medtronics, Johnson & Johnson, GE, and Stryker.

    By Amritpal Khalsa
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Eli Lilly Rose on FDA’s Approval of Basaglar

    Eli Lilly (LLY) gained 0.9% on December 16, 2015. The stock went up on the news that the FDA (US Food and Drug Administration) approved Basaglar.

    By Peter Neil
  • uploads///hospital _
    Company & Industry Overviews

    Boston Scientific Stock in the Week Ended September 14

    Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.

    By Sarah Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Waters Introduces Symphony, Its New Data Pipeline Software

    A top IHI performer on June 2, 2016, was Waters (WAT), which rose 0.9%. The company was in the news with the introduction of its new data pipeline software.

    By Peter Neil
  • uploads///Watson acquisitions
    Miscellaneous

    IBM Boosted Watson Capabilities through Strategic Acquisitions

    IBM (IBM) is betting heavily on Watson, its cognitive computing platform, to steer the company towards much-needed growth.

    By Anne Shields
  • uploads///rhythm management
    Company & Industry Overviews

    FDA Approves Boston Scientific’s Emblem MRI S-ICD System

    Boston Scientific (BSX) offers a leading portfolio of rhythm management devices around the world.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    How Will Abbott Laboratories Benefit from Its Alere Acquisition?

    On April 14, 2017, Abbott Laboratories (ABT) agreed to acquire point-of-care diagnostics player Alere (ALR) for an equity value of ~$5.3 billion.

    By Margaret Patrick
  • uploads///watson
    Company & Industry Overviews

    IBM Is Paving the Way for Watson Health: Acquisitions and Deals

    IBM’s partnership with Apple is especially appealing. Watson Health will bring cloud services and analytics to Apple’s HealthKit and ResearchKit.

    By Anne Shields
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Baxalta Rose on FDA’s Approval of Vonvendi

    Baxalta (BXLT) rose by 0.7% on December 9, 2015. The stock moved up as the FDA (US Food and Drug Administration) approved its drug Vonvendi.

    By Peter Neil
  • uploads///analyst recommendations
    Company & Industry Overviews

    Wall Street Maintains ‘Strong Buy’ Recommendation for Stryker

    Analysts’ recommendations Stryker (SYK) has registered strong results over the last few quarters and has been expanding at a fast pace through organic and inorganic growth. The company has made a number of acquisitions and expanded its market presence across product lines and regions. Its most recent earnings results were reported on October 26, 2017. For details, read […]

    By Sarah Collins
  • uploads///geographic strength
    Company & Industry Overviews

    How BD-Bard Acquisition Will Strengthen International Presence

    C.R. Bard (BCR) has grown significantly outside the United States in recent years, driven by its international channel expansion strategy.

    By Sarah Collins
  • uploads///medical device segment
    Company & Industry Overviews

    Abbott’s Freestyle Libre Gets Reimbursement Approval in France

    Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.

    By Sarah Collins
  • uploads///key strategies
    Company & Industry Overviews

    Understanding Zimmer Biomet’s Latest Dividend Announcement

    On December 18, 2017, Zimmer Biomet Holdings (ZBH) announced a quarterly cash dividend of $0.24 per share for fiscal 4Q17.

    By Sarah Collins
  • uploads///Diabetes
    Company & Industry Overviews

    What to Expect from Medtronic’s Diabetes Segment

    In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depository share.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.